Skip to main content
IOVANCE BIOTHERAPEUTICS, INC. logo

IOVANCE BIOTHERAPEUTICS, INC. — Investor Relations & Filings

Ticker · IOVA ISIN · US4622601007 LEI · 2549002L8WT2ACU5Q878 US Manufacturing
Open in API
Filings indexed 831 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country US United States of America
Listing US IOVA

About IOVANCE BIOTHERAPEUTICS, INC.

https://www.iovance.com/

Iovance Biotherapeutics, Inc. is a commercial-stage biopharmaceutical company focused on innovating, developing, and delivering cell therapies for cancer. The company's core technology is Tumor Infiltrating Lymphocyte (TIL) therapy, a personalized immunotherapy that harnesses a patient's own immune system. The process involves extracting T-cells from a patient's tumor, expanding them, and re-infusing them to recognize and attack cancer cells by targeting unique neoantigens. Iovance is investigating its T-cell-based therapies in clinical trials for various advanced solid tumors, such as metastatic melanoma. The company is also advancing genetically modified TIL therapies as a next-generation approach to cancer treatment.

Recent filings

Filing Released Lang Actions
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Regulatory Filings Classification · 89% confidence The document is a Form 8-K current report filed by Iovance Biotherapeutics under the Securities Exchange Act. It does not contain the full financial statements but merely indicates that a press release with first quarter results is furnished as Exhibit 99.1. It is a regulatory compliance filing rather than the actual earnings release or interim report itself. Therefore, it falls under the Regulatory Filings (RNS) category.
2026-05-07 English
10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
ARS - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Annual Report
2026-05-01 English
DEF 14A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Proxy Solicitation & Information Statement
2026-04-28 English
8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports on significant events. The content specifically announces the departure and retirement of a board member, Wendy Yarno, from the company's Board of Directors. This type of announcement fits the category of changes in the company's board or senior management. The document does not contain financial data, audit information, or other report types. Therefore, it is best classified as Board/Management Information (MANG). The document length is 3838 characters, which is consistent with a typical 8-K announcement rather than a full report.
2026-03-20 English
4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)
Director's Dealing
2026-02-26 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.